SciGen's portfolio currently includes 6 biopharmaceutical products, one hepatitis B vaccine and SciTojet2™, a drug delivery device.  Patents of several biopharmaceutical products with a market value of over $20 billion have expired this provides an opportunity for SciGen’s expansion.